Rimonabant for Cognitive Impairment in People With Post-COVID-19 Syndrome

Ki vehet részt

• Age between 18 and 75 years (both inclusive)
• Have had COVID-19 at least 3 months before joining the study
• Have been diagnosed with active PCS (Long COVID)
• Have ongoing problems with memory or concentration due to long-COVID syndrome
• Show signs of cognitive impairment in study assessments
• Be willing to complete study assessments
• Be able to understand and speak Spanish
• Provide written consent to participate

Ki nem vehet részt

• Use substances or medications that may affect memory or concentration
• Have an active or recent COVID-19 infection
• Have severe mental health conditions, a pprevious suicide attempt
• Have neurological conditions that may affect memory or concentration
• Have other medical conditions that could explain their symptoms
• Have severe lung, heart, liver, kidney, or bone disease
• Have a known allergy to rimonabant
• Have a high risk of suicide
• Have a body mass index (BMI) greater than 40 kg/m²
• Are unable to walk or attend study visits
• Are taking medicines that may interact with the study treatment
• Have taken part in another clinical trial within the last month
• Are pregnant or breastfeeding
• Are able to become pregnant or father a child and are not using effective contraception